Hidden HER-2/neu-positive breast cancer: How to maximize detection

IDrugs

Volumn 12, Issue 4, 2009, Pages 238-242

  Carney, Walter P ^a  

^a Siemens Healthcare Diagnostics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; ONCOPROTEIN; TRASTUZUMAB;

ALGORITHM; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; EARLY CANCER; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; REVIEW;

ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; RECEPTOR, ERBB-2; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 64349086161     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. Carney W, Leitzel K, Ali SM, Neumann R, Lipton A: HER-2/neu diagnostics in breast cancer. Breast Cancer Res (2007) 9(3):207.
2. Regitnig P, Schippinger W, Lindbauer M, Samonigg H, Lax SF: 2. Change of HER-2/neu/neu status in a subset of distant metastases from breast carcinomas. J Pathol (2004) 203(4):918-926.
3. Santinelli A, Pisa E, Stramazzotti D, Fabris G: 3. HER-2/neu status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int J Cancer (2008) 122(5):999-1004.
4. Fehm T, Gebauer G, Jager W: 4. Clinical utility of serial serum c-erB-2 determinations in the follow-up of breast cancer patients. Breast Cancer Res Treat (2002) 75(2):97-106.
5. Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, 5. Lingle WL, Flynn PJ, Ingle JN, Visscher D, Jenkins RB: HER-2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 Intergroup Adjuvant trial. J Clin Oncology (2006) 24(19):3032-3038.
6. Beny A, Zidan J, Dashkovsky I, Cozacov C, Hadary A, Basher 6. W: Evaluation of HER-2/neu in primary breast cancer and metastatic sites. Am Soc Clin Oncol (2002):Abs 2991.
7. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, 7. Beitsch P, Khan A, Euhus D, Osborne C, Frenkel E et al: HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA (2004) 101(25):9393-9398.
8. Fehm T, Becker S, Duerr-Stoerzer S, Sotlar K, Mueller V, 8. Wallwiener D, Lane N, Solomayer E, Uhr J: Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res (2007) 9(5):R74.
9. Paik S, Kim C, Jeong J, Geyer CE, Romond EH, Mejia-Mejia O, 9. Mamounas EP, Wickerham D, Constantino JP, Wolmark N: Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH positive tumors. Central testing results from NSABP B31. J Clin Oncol (2007) 25(Suppl 18):Abs 511.
10. Ardavanis A, Kountourakis P, Kyriakou F, Malliou S, Mantzaris I, 10. Garoufali A, Yiotis I, Scorilas A, Baziotis N, Rigatos G: Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer. Oncologist (2008) 13(4):361-369.
11. Harris L11. , Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr, American Society of Clinical Oncology: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol (2007) 25(33):5287-5312.